Calendario›REGN›dupilumab · EDESIA
dupilumab · EDESIA
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Ensayo de REGENERON PHARMACEUTICALS, INC. en Eosinophilic Esophagitis (EoE) (del registro, en inglés).
- Fase
- no aplica
- Estado
- En marcha, sin reclutar
- Participantes
- 368
- Centros
- 54
- Fin del objetivo primario
- may 2030
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en nov 2024.
Qué mide
Demographic characteristic of participants who receive dupilumab for EoE: Age (Baseline and up to 3 years after treatment initiation) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06693531), actualizada en ago 2026.